Loading...
OTCM
BCLI
Market cap10mUSD
Oct 08, Last price  
0.91USD
1D
1.51%
1Q
-15.40%
Jan 2017
-97.60%
IPO
-98.73%
Name

Brainstorm Cell Therapeutics Inc

Chart & performance

D1W1MN
OTCM:BCLI chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
32.64%
Rev. gr., 5y
%
Revenues
0
0000000000000-366,000000000
Net income
-10m
L
-3,924,485-6,244,000-3,472,000-1,781,000-2,419,000-3,918,000-3,430,000-4,899,000-9,246,000-8,488,000-4,982,000-4,952,000-13,948,000-23,253,000-31,811,000-24,457,000-24,277,000-17,192,00011,623,000-10,307,000
CFO
-7m
L-23.29%
-855,000-1,774,000-1,734,000-744,000-2,069,000-2,223,000-2,916,000-4,054,000-4,487,000-7,408,000-5,858,000-2,364,000-12,388,000-11,247,000-35,193,000-26,265,000-19,320,000-20,458,000-9,093,000-6,975,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.

Key people

Ralph Kern
President, Chief Medical Officer · since 2020
Alla Patlis
Interim Chief Financial Officer · since 2016
Stacy Lindborg
Executive Vice President Head of Global Clinical Research · since 2020
Preetam Shah
Chief Financial Officer, Executive Vice President, Treasurer · since 2019
Eyal Rubin
Chief Financial Officer, Treasurer · since 2017
Arturo O. Araya
Chief Commercial Officer · since 2018
Irit Arbel
Vice Chairman of the Board · since 2020
Uri Yablonka
Executive Vice President, Chief Business Officer, Director · since 2017
June Almenoff
Independent Director · since 2017
Malcolm S. Taub
Independent Director · since 2009
URL
https://brainstorm-cell.com/
IPO date
May 28, 2003
Employees
44
Domiciled in
US
Incorporated in
US
Legal address
c/o The Corporation Trust Company, Corporation Trust Center 1209 Orange St
Wilmington, DE 19801
US
Headquarters
1325 Avenue of Americas
New York, NY 10019
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT